Industry Watch
Eating chips three times a week raises type 2 diabetes risk by 20%, study finds
12th August 2025
Eating french fries three times a week increases the risk of people getting type 2 diabetes by 20%; doing this five times a week increases the risk by 27% – according to a study published in the British Medical Journal.
The results confirm that potatoes do not cause a risk to health, but frying potatoes to make chips, and consuming them regularly, does increase the risk of diagnosis of type 2 diabetes.
The researchers who conducted the study, led by Seyed Mohammad Mousavi, a public health expert at Harvard University, examined the relationship between the intake of potatoes and the risk of acquiring type 2 diabetes.
Smaller portions and high protein, the 'Ozempic menu' has arrived in Dubai
12th August 2025
A Dubai restaurant, The Banc, has introduced a smaller-portion, high-protein menu designed for diners who use weight-loss injections.
The Banc has stated that the Mini Bancer menu includes its most popular drinks and dishes, but using lighter portions. The menu includes a half-sized grilled sea bream and barbecue melt chicken, and also smaller portion starters, such as tiger prawns, lamb kebabs and Wagyu beef tartare.
The Banc Dubai has stated that the menu was first tried out at the London location prior to being introduced in the UAE.
Announcing the IDDSI Academy UK official training pilot - 15th September 2025
IDDSI Global is pleased to introduce the first IDDSI Academy Pilot course in the UK, at St. Michael’s Centre, Bristol.
The pilot course consists of two parts: a compulsory online learning section (to be completed before the in-person training) and an in-person training day on the IDDSI framework, practical application, testing methods, and hands-on practice.
This is suitable for all IDDSI users including catering managers, chefs, care teams and nurses. Spaces are limited to 80 delegates.
Semaglutide emerges as contender in cerebrovascular disease management, says GlobalData
30th July 2025
GlobalData, a leading data and analytics company have highlighted the potential of semaglutide to improve outcomes in brain haemorrhage and stroke patients driven by its anti-inflammatory and cardiovascular effects due to recent clinical findings.
Costanza Alciati, Pharma Analyst at GlobalData has stated "In the past couple of weeks new results came out from three studies investigating the use of semaglutide in stroke and brain hemorrhage patients. Semaglutide seems to increase the chance of surviving in patients experiencing stroke and reduce related complications. It also seems to have a similar impact in patients experiencing brain hemorrhage, reducing side effects, seizures, future reoccurrence and death."
